Solvonis Therapeutics (SVNS) AI Stock Analysis

• Market Cap: £20.22M
• Dividend Yield: N/A
• Average Volume (3M): 34.43M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 3
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Machinery
• EPS (TTM): 0.00
• Shares Outstanding: 6,806,403,300
• 10 Day Avg. Volume: 23,401,787
• 30 Day Avg. Volume: 34,434,652
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: 0.32p ▼(-8.57% Downside)

The score is held down primarily by weak fundamentals (zero revenue in 2024, ongoing losses, and continued cash burn), despite the benefit of a low-debt balance sheet. Technical indicators are supportive (price above key moving averages with positive MACD), but missing P/E and dividend yield data limits valuation assessment.

Solvonis Therapeutics Business Overview & Revenue Model

Company Description

Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous polymer-carriers for use in liquid chemicals. It also provides GRAFTAMID, a line of high-temperature elastomers based on nanostructured polyolefin-polyamide alloys for high-tech hardening modifiers in polyamide compounds, as well as use as an independent compound in hot melt adhesives; and GRAFTAKIT, a reactive liquid or solid super-concentrates on polymeric porous media for carrying out reaction extrusion and modification of compounds. In addition, the company offers GRAFTALLOY, a line of polymer-polymer nano-alloys to increase abrasion and temperature resistance, and impact strength, as well as reduce friction coefficient; GRAFTASYNT, a line of synthetic products comprising halogen-free flame retardants; and GRAFTAMER, a thermo-reversible crosslinking, self-hardening, and self-healing smart polymer with shape memory, etc. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Solvonis Therapeutics Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	587.00K	542.00K	219.00K	690.86K
Gross Profit	0.00	-134.00K	-51.00K	55.00K	517.72K
EBITDA	-1.38M	-2.94M	-2.59M	-900.00K	-322.29K
Net Income	-1.59M	-3.12M	-2.71M	-954.00K	-274.29K
Balance Sheet
Total Assets	3.20M	2.43M	4.94M	3.13M	2.77M
Cash, Cash Equivalents and Short-Term Investments	757.00K	155.00K	1.64M	598.00K	209.00K
Total Debt	0.00	34.00K	22.00K	950.00K	654.00K
Total Liabilities	119.00K	408.00K	385.00K	2.32M	1.22M
Stockholders Equity	3.08M	2.03M	4.55M	812.00K	1.54M
Cash Flow
Free Cash Flow	-1.13M	-1.47M	-3.08M	-255.00K	-15.00K
Operating Cash Flow	-1.13M	-1.24M	-2.36M	-254.00K	1.00K
Investing Cash Flow	-337.00K	-232.00K	-718.00K	-1.00K	-16.00K
Financing Cash Flow	2.08M	0.00	4.13M	800.00K	199.00K

Solvonis Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEPS	67 Neutral	£7.35M	17.33	15.40%	―	6.46%	-32.89%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
PEG	61 Neutral	£6.37M	-12.50	-8.06%	―	63.81%	71.62%
SVNS	50 Neutral	£20.22M	―	―	―	―	―
SNT	44 Neutral	£2.01M	-2.73	-2231.03%	―	19.13%	-8.13%
THRU	42 Neutral	£4.25M	-0.52	-71.37%	―	-21.55%	10.59%

Solvonis Therapeutics Corporate Events

Solvonis Wins U.S. Patent Boost for Novel PTSD Drug Programme

Solvonis Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office covering a novel series of compounds within its SVN-SDN-14 PTSD discovery programme, bolstering the intellectual property position of this early-stage asset as the company moves toward selecting a lead candidate in the first quarter of 2026. The newly protected compounds are designed to modulate serotonin, dopamine and noradrenaline pathways while offering improved pharmacokinetic control through predictable metabolic deactivation, a feature the company says could translate into safer, more flexible dosing and greater real-world clinical utility, strengthening both the scientific validation and commercial prospects of Solvonis’s PTSD franchise in the competitive CNS therapeutics landscape.

The most recent analyst rating on (GB:SVNS) stock is a Hold with a £0.32 price target. To see the full list of analyst forecasts on Solvonis Therapeutics stock, see the GB:SVNS Stock Forecast page.

Solvonis Therapeutics Maps Out Catalyst-Rich 2026 as CNS Pipeline Gains Momentum

Solvonis Therapeutics reported broad progress across its CNS pipeline as it heads into what it describes as a catalyst-rich 2026, highlighting advancement of its lead alcohol use disorder (AUD) and PTSD programmes alongside AI-driven discovery efforts. Lead candidate SVN-001 is moving through a potentially pivotal Phase 3 trial for severe AUD in a large, underserved UK and EU population, while SVN-002, an esketamine oral thin film for moderate-to-severe AUD, is being prepared for a U.S. Phase 2b trial via an FDA 505(b)(2) pathway that could materially reduce development time and cost. The company also secured external validation for its AI-enabled platform with SVN-015’s acceptance into the U.S. National Institute on Drug Abuse’s Addiction Treatment Discovery Program, which brings NIDA-funded preclinical work and potential access to further non-dilutive NIH development funding for stimulant use disorder. Meanwhile, PTSD candidate SVN-SDN-14 is nearing lead selection ahead of IND-enabling studies, and Solvonis says the integration of Awakn Life Sciences earlier in 2025 has created a more diversified CNS platform, positioning the group with multiple regulatory, preclinical and partnering milestones that could enhance both its industry standing in addiction psychiatry and its long-term value proposition for shareholders.

Solvonis’ SVN-015 Accepted into NIDA Program for Addiction Treatment

Solvonis Therapeutics has announced that its AI-discovered compound, SVN-015, has been accepted into the US National Institute on Drug Abuse’s Addiction Treatment Discovery Program for methamphetamine and cocaine addiction. This acceptance marks a significant milestone for Solvonis, as it expands its research into stimulant addictions, which currently have no approved drug treatments. The program will initially involve preclinical safety studies, potentially leading to efficacy studies and further NIH funding. This development could enhance Solvonis’ position in the CNS disorder treatment market and provide new opportunities for addressing critical unmet needs in addiction treatment.

Solvonis Therapeutics Updates Share Capital Details

Solvonis Therapeutics has announced an update regarding its issued share capital, confirming a total of 6,806,403,493 Ordinary Shares with one voting right each. This adjustment, which corrects a previous share issuance figure, is significant for shareholders as it affects calculations related to their shareholding interests.

Solvonis Therapeutics Streamlines Operations and Enhances R&D Focus

Solvonis Therapeutics has announced a corporate restructuring to streamline its operations and focus on research and development. This includes the reorganization of its subsidiaries in Ireland, the UK, and the US, and the disposal of a non-core subsidiary, Graft Polymer IP Limited, to consolidate intellectual property and enhance R&D capabilities. The company also issued new shares to settle historical liabilities and granted share options to its CEO and non-executive directors, reflecting its commitment to strategic transformation and stakeholder alignment.

Solvonis Therapeutics Appoints Paul Carter as Non-Executive Director

Solvonis Therapeutics has appointed Paul Carter as a Non-Executive Director to support its strategic growth. Carter’s extensive experience in the biopharmaceutical industry is expected to enhance Solvonis’ efforts in advancing its CNS pipeline and executing a capital-efficient, licensing-first growth strategy. This appointment is anticipated to strengthen the company’s board and contribute to its sustainable growth, benefiting both patients and shareholders.

Solvonis Therapeutics Raises £1.25 Million to Boost CNS Disorder Programs

Solvonis Therapeutics plc has successfully raised £1.25 million through a direct subscription with institutional and strategic investors to accelerate its programs in high-burden CNS disorders. This funding will support the company’s expanded three-pillar strategy focusing on addiction, psychiatry, and neurology, enabling Solvonis to advance its clinical and pre-clinical programs, expand its CNS drug-discovery efforts, and strengthen its R&D capabilities. The investment marks a significant step in Solvonis’ growth as it aims to deliver innovative therapies for CNS disorders, enhancing its industry positioning and providing a foundation for continued scientific and clinical progress.